艾曲泊帕治疗一线激素难治或复发成人ITP患者停药后持续缓解:II期TAPER试验的主要、最终及事后分析
TAPER是一项II期前瞻性单臂试验,评估艾曲泊帕能否使一线激素治疗失败的成人ITP患者获得停药后持续缓解(SRoT)。至第12个月,30.5%(32/105;P<.0001)的患者达到SRoT,中位SRoT持续时间约8个月;事后分析提示艾曲泊帕在新诊断和后期ITP中疗效相似,随访至第24个月中位SRoT约22个月(n=20)。
要点
- 至第12个月,30.5%(32/105;P<.0001)的患者在艾曲泊帕减量停药后达到SRoT。
- 至第12个月中位SRoT持续时间约8个月,中位血小板计数在治疗1个月内升高并维持至第12个月。
- 头痛(21%)是最常见不良事件,4例死亡均不被认为与治疗相关。
核心结论
- 约三分之一患者在接受艾曲泊帕减量并停药后至第12个月达到SRoT。
- 事后分析结果提示艾曲泊帕在新诊断和后期ITP中疗效相似。
研究设计与样本
- TAPER(NCT03524612)是一项II期、前瞻性、单臂试验,纳入一线糖皮质激素治疗失败的成人ITP患者,研究艾曲泊帕能否诱导停药后持续缓解(SRoT)。
- SRoT定义为停药期间血小板计数维持高于30 × 109/L且无出血或救援治疗。
- 主要终点为至第12个月达到SRoT的患者比例。
主要发现
- 至第12个月,30.5%(n=32/105;P<.0001,检验假设H1:比例>15%)的患者在艾曲泊帕减量停药后达到SRoT。
- 至第12个月中位SRoT持续时间约8个月,中位血小板计数在治疗1个月内升高并维持至第12个月。
- 生活质量在3个月内改善并得以维持。
- 头痛(21%)是最常见不良事件,4例死亡均不被认为与治疗相关。
- 事后早期使用分析按基线ITP病程分层评估初始血液学应答和安全性,结果提示艾曲泊帕在新诊断和后期ITP中疗效相似;随访至第24个月观察到中位SRoT持续时间约22个月(n=20)。
关键数值与推荐
- SRoT定义为停药期间血小板计数维持高于30 × 109/L且无出血或救援治疗。
- 主要终点至第12个月达到SRoT的比例为30.5%(n=32/105;P<.0001,检验假设H1:比例>15%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is characterized by reduced platelet count due to increased destruction and is categorized according to the time following diagnosis (newly diagnosed, persistent, chronic). First-line corticosteroid therapy is associated with transient response, high relapse rates, and considerable toxicity. TAPER (NCT03524612) is a Phase II, prospective, single-arm trial investigating whether eltrombopag can induce a sustained response off-treatment (SRoT) in adult patients with ITP after first-line corticosteroid failure. This study defines SRoT as an off-treatment period wherein platelet count remains above 30 × 109 /L in the absence of bleeding or rescue therapy. The primary endpoint was the proportion of patients who achieved SRoT until Month 12, which was 30.5% (n = 32/105; p < .0001 testing hypothesis H1: proportion >15%) following eltrombopag tapering and discontinuation, and median SRoT duration was ~8 months until Month 12. Median platelet count increased within 1 month of treatment and remained elevated until Month 12. Quality of life improved within 3 months and was maintained. Headache (21%) was the most common adverse event. None of the 4 deaths reported were considered treatment-related. In summary, ~one-third of patients achieved SRoT until Month 12 following eltrombopag tapering and discontinuation. An ad-hoc early-use analysis, stratified by ITP duration at baseline, assessed initial hematologic responses and safety. Results suggest that eltrombopag has similar efficacy in newly diagnosed and later stages of ITP. In follow-up until Month 24, a median SRoT duration of ~22 months was observed (n = 20). The safety profile was comparable across analyses and ITP duration groups and aligned with its well-established safety profile.
引用
- Cooper N, Ghanima W, Vianelli N, et al. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Am J Hematol. 2023. PMID: 38014779. doi:10.1002/ajh.27131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。